(Total Views: 553)
Posted On: 08/28/2020 10:43:13 AM
Post# of 72440
Drano has something been announced that makes you think B-UC progress has been slowed? I don't remember seeing that. This is from February PR and before IPIX even pocketed $6mm. I'm assuming UC is still on track.
The Company remains committed to its prioritization of ongoing clinical development of Brilacidin for Inflammatory Bowel Disease and Oral Mucositis in Head and Neck Cancer patients. As to Brilacidin’s antiviral properties, the strategy is to explore research collaborations and federal grant opportunities to further evaluate the drug’s potential to treat Coronaviruses without tapping into resources dedicated for clinical research in Brilacidin’s primary indications.
The Company plans to keep shareholders apprised, as appropriate, on any news related to evaluating Brilacidin’s antiviral properties in addition to its core Brilacidin programs, Ulcerative Colitis and Oral Mucositis.
The Company remains committed to its prioritization of ongoing clinical development of Brilacidin for Inflammatory Bowel Disease and Oral Mucositis in Head and Neck Cancer patients. As to Brilacidin’s antiviral properties, the strategy is to explore research collaborations and federal grant opportunities to further evaluate the drug’s potential to treat Coronaviruses without tapping into resources dedicated for clinical research in Brilacidin’s primary indications.
The Company plans to keep shareholders apprised, as appropriate, on any news related to evaluating Brilacidin’s antiviral properties in addition to its core Brilacidin programs, Ulcerative Colitis and Oral Mucositis.
(4)
(0)
Leo Took The Money and Ran
Scroll down for more posts ▼
